Ouédraogo D D, Lompo C P, Tiéno H, Bognounou R, Diendéré A E, Sawadogo A, Zoungrana L, Drabo J Y
Service de médecine interne, Centre hospitalier et universitaire Yalgado Ouédraogo de Ouagadougou, Burkina Faso.
Med Trop (Mars). 2010 Aug;70(4):345-8.
The purpose of this report is to describe epidemiological aspects of rheumatic disorders observed in HIV-infected patients undergoing highly active antiretroviral therapy (HAART). Patients and methods. This cross-sectional study was conducted from January 1 to June 30, 2008 in the HIV unit of an internal medicine department in Burkina Faso. All patients who had been undergoing HAART for at least one year were included. Interviewing and thorough physical examination were performed in all cases. Radiography of the pelvis and hip was performed in some patients. Bone densitometry was never performed.
A total of 366 patients including 265 women and 101 men (sex ratio of 0.38) were included. Mean patient age was 39.61 +/- 8.54 years. Three hundred and thirty-five patients (91.53%) were positive for HIV1, 17 (4.64%) for HIV2 and 14 (3.83%) for both HIV1 and HIV2. Mean duration of infection was 3.58 +/- 1.88 years. Mean CD4 cell count was 394.20 cell/microL. A recent HIV viral load determination was available for 285 patients including 262 who had no detectable virus. Mean duration of HAART was 35.80 +/- 15.17 months. Only 61 patients (16.66%) were treated with protease inhibitor (PI). The prevalence of rheumatic disorders was 5.73% (21 cases). A variety of disorders were observed, i.e., lower back pain in 8 patients (38.1%), arthralgia in 4 patients including 2 treated with PI, osteoarthritis of the knee in 2 patients, Pott disease in 2 patients, De Quervain disease in 2 patients including one treated with PI, tendinitis of the shoulder in one patient treated with PI, gout in one patient treated with PI and unclassifiable inflammatory rheumatism in one patient. No case of symptomatic osteonecrosis or osteoporosis was observed.
Rheumatic disorders are uncommon in the HIV-infected patients undergoing HAART in Burkina Faso. The most likely explanation is that PI is not widely used.
本报告旨在描述接受高效抗逆转录病毒治疗（HAART）的HIV感染患者中观察到的风湿性疾病的流行病学特征。患者与方法。本横断面研究于2008年1月1日至6月30日在布基纳法索一家内科的HIV科室进行。纳入所有接受HAART至少一年的患者。对所有病例进行访谈和全面体格检查。部分患者进行了骨盆和髋部的X线检查。从未进行骨密度测定。
共纳入366例患者，其中女性265例，男性101例（性别比为0.38）。患者平均年龄为39.61±8.54岁。335例（91.53%）患者HIV1阳性，17例（4.64%）HIV2阳性，14例（3.83%）HIV1和HIV2均阳性。平均感染持续时间为3.58±1.88年。平均CD4细胞计数为394.20个/微升。285例患者有近期HIV病毒载量测定结果，其中262例未检测到病毒。HAART的平均持续时间为35.80±15.17个月。仅61例患者（16.66%）接受蛋白酶抑制剂（PI）治疗。风湿性疾病的患病率为5.73%（21例）。观察到多种疾病，即8例患者出现下背痛（38.1%），4例患者有关节痛，其中2例接受PI治疗，2例患者有膝关节骨关节炎，2例患者有波特病，2例患者有桡骨茎突狭窄性腱鞘炎，其中1例接受PI治疗，1例接受PI治疗的患者有肩部肌腱炎，1例接受PI治疗的患者有痛风，1例患者有无法分类的炎性风湿病。未观察到有症状的骨坏死或骨质疏松病例。
在布基纳法索接受HAART的HIV感染患者中，风湿性疾病并不常见。最可能的解释是PI未广泛使用。
